Clinical trial
Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment…
NCT00437658 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT00437658 |
|---|---|
| Title | Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis |
| Official title | A Phase II, Randomized, Double-blind, Active-controlled Study to Assess the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis |
| Acronym | PETAL |
| Lead sponsor | AbbVie, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometriosis |
| Intervention type | Drug |
| Interventions | Elagolix, Subcutaneous depot medroxyprogesterone acetate (DMPA-SC), Placebo to Elagolix, Placebo to DMPA-SC |
| Enrollment | 252 |
| Start date | Dec 11, 2006 |
| Primary completion | Nov 24, 2008 |
| Completion | Nov 24, 2008 |
| First posted | Feb 21, 2007 |
| Last update posted | Oct 12, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: